Quantcast
Home > Quotes > CHMA

Chiasma, Inc. Common Stock (CHMA) Quote & Summary Data

CHMA 
$5.94
*  
0.10
1.71%
Get CHMA Alerts
*Delayed - data as of Apr. 18, 2019  -  Find a broker to begin trading CHMA now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    CHMA After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 4.10 / $ 6.30
1 Year Target
14
Today's High / Low
$ 5.96 / $ 5.76
Share Volume
114,408
50 Day Avg. Daily Volume
167,048
Previous Close
$ 5.84
52 Week High / Low
$ 7.1875 / $ 1.20
Market Cap
188,468,223
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -1.28
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
-0.22

Intraday Chart

Shares Traded

Share Volume:
114,408
50 Day Avg. Daily Volume:
167,048

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.28

Trading Range

The current last sale of $5.94 is 395.00% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 5.96 $ 7.1875
 Low: $ 5.76 $ 1.20

Company Description (as filed with the SEC)

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients who face challenges associated with their existing treatments for rare and serious chronic disease. Employing our proprietary Transient Permeability Enhancer, or TPE, technology platform, we seek to develop oral medications that are currently available only as injections. We are currently evaluating oral octreotide capsules, conditionally trade-named "MYCAPSSA", our sole TPE platform-based clinical product candidate, in two Phase 3 clinical trials in adult patients for the treatment of acromegaly to potentially support regulatory approval in the United States and European Union. Acromegaly is a rare and debilitating condition that results in the body's production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion.  ... More ...  



Risk Grade

Where does CHMA fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 5.81
Open Date:
Apr. 18, 2019
Close Price:
$ 5.94
Close Date:
Apr. 18, 2019


Consensus Recommendation

Analyst Info